National MS Registry of Iran

“2025”

1. Investigating the rate of progression of MS among subjects with COVID-19 infection – A National MS Registry- based Study/ 10th MENACTRIMS  Congress 2025/ UAE, Dubai
2. Examination and assessment of the COVID-19 severity symptoms among patients with multiple sclerosis: A national registry-based case-control study/ 10th MENACTRIMS  Congress 2025/ UAE, Dubai
3. Developing MS Care and Research by Planning a National MS Registry System in Iran/ 10th MENACTRIMS  Congress 2025/ UAE, Dubai
4. COVID-19 severity among patients with multiple sclerosis: A national registry-based study/ ECTRIMS 2025, Spain
5. Familial and Epidemiology of Multiple Sclerosis in Tehran, Iran/ ECTRIMS 2025, Spain
6. The Association of Urogenital Symptoms with Clinical, Demographic, and Treatment Factors in Multiple Sclerosis subjects: Findings from the National MS Registry/ ECTRIMS 2025, Spain
7. THE MANAGEMENT METHOD OF NATIONAL MULTIPLE SCLEROSIS REGISTRY SYSTEM IN IRAN/ 4th Joint Congress of the INS European Chapters 2025, Istanbul, Turkey
8. Addressing Over fitting in Imbalanced Dataset for MS Progression Prediction/ ICICT 2025, London, UK

“2024”

1. Urological Symptoms in Iranian Patients with Multiple Sclerosis: Prevalence, Characteristics, and Associations with DMDs for optimum Management / ECTRIMS 2024 – 40th Congress of ECTRIMS / Copenhagen, Denmark
2. AI-Driven Stratification of Multiple Sclerosis Subtypes: A Study on Clinical Feature-Based Classification in Iranian Patients / ECTRIMS 2024 – 40th Congress of ECTRIMS  / Copenhagen, Denmark
3. Patterns and Determinants of Disease-Modifying Drug Changes in Multiple Sclerosis Patients in Tehran: An Analysis of the Nationwide MS Registry of Iran / ECTRIMS 2024 – 40th Congress of ECTRIMS  / Copenhagen, Denmark
4. Uncovering Environmental Risk Factors of Late-Onset Multiple Sclerosis: A Population-Based Case-Control Study from Iran / ECTRIMS 2024 – 40th Congress of ECTRIMS  / Copenhagen, Denmark

“2023”

1. Uncovering Trends and Patterns in Disease Modifying Drug Use and Change: A Cross-Sectional Study from the Tehran MS Registry, Iran / ECTRIMS 2023
2. Evaluating the Influential Factors on the Time Interval between the Symptoms Onset and Diagnosis of Patients with Multiple Sclerosis / ECTRIMS 2023
3. Parental Consanguinity and the Age at Onset in Multiple Sclerosis: A National Registry-Based Analysis of Familial Cases of Iran / MENACTRIMS 2023
4. Revolutionizing MS Care and Research: Inside Iran’s Nationwide Multiple Sclerosis Registry / MENACTRIMS 2023
5. Prevalence and Clinical Characteristics of Urological Symptoms in Iranian Multiple Sclerosis Patients: Implications for Quality of Life and Management / MENACTRIMS 2023

“2022”

1. Epidemiology of Multiple Sclerosis in Iran in 2021 / ECTRIMS 2022
2. The Association Between Reproductive Characteristics and Disability in Iranian Female Patients with Multiple Sclerosis a Nationwide Registry-based Cross-sectional Study / ECTRIMS 2022
3. The Rate and Pattern of Changes in MS Disease Modifying Drugs in Tehran, Iran; a Cross-Sectional Study from Tehran MS Registry / MENACTRIMS 2022
4. Is there a Link Between Multiple Sclerosis and Pregnancy in Terms of Tendency, Reproductive Characteristics, and Disability? A Secondary Data Analysis of Nationwide MS Registry of Iran / MENACTRIMS 2022
5. Rate of Parental Consanguineous Marriage Among Familial Multiple Sclerosis Patients in Iran: A National Registry-Based Study / MENACTRIMS 2022
6. Predicting COVID-19 Infection in MS patients using discriminant analysis model / MENACTRIMS 2022
7. Epidemiological parameters of multiple sclerosis in Chaharmahal- Bakhtiari province, Iran / MENACTRIMS 2022
8. Epidemiology of MS in Iran (What we know from the MS registry) / 29th International Congress of Clinical Neurology and Electrophysiology of Iran, 2022

“2021”

1. Bayesian Structural Time Series of Multiple Sclerosis Projection in Tehran, Iran / ECTRIMS 2021
2. Epidemiology of COVID-19 among MS Population Population-Based Registry Study in Iran / ECTRIMS 2021
3. Famlial Multiple Sclerosis Risk in Iran A population-based registry study / ECTRIMS 2021
4. Determining the Effect of Sun Exposure and Physical Activity on the Incidence of PPMS / ECTRIMS 2021
5. Prevalence of MS in Tehran, Iran in 2020 and its forecast for the next 10 years / MENACTRIMS 2021
6. Challenges of MS Patients for Receiving Health Care Services / MENACTRIMS 2021
7. Epidemiology of COVID-19 in MS patients: A Population-Based Registry Study in Iran / MENACTRIMS 2021
8. Water-pipe and cigarette smoking, drug abuse and alcohol consumption and the risk of primary progressive multiple sclerosis: A population-based case-control study / MENACTRIMS 2021

“2020”

1. Epidemiology and MS Prevalence in Tehran Province, Iran / ECTRIMS 2020
2. Integration of COVID-19 databases into the Iranian National Multiple Sclerosis Registry System / National Virtual Conference on COVID-19 Research Achievements in the Country- 2020

“2018”

• 1. Validity and Reliability of National Multiple Sclerosis Form for Registry System in Iran / ECTRIMS 2018
  2. Principles for Planning National MS Registry System and Impact on Patient Care and Health Outcomes / MENACTRIMS 2018
  3. Multiple Sclerosis Minimum Data Set for National Registry System in Iran- Definition Validity and Reliability / MENACTRIMS 2018
  4. Second International Conference on Disease and Health Outcomes- 2018:
     1. Principles for Planning National MS Registry System and its Impact
     2. Validity and Reliability of Information Items of Iran’s MS Registry System